Literature DB >> 3112864

Malignant melanoma: analysis of dose fractionation in radiation therapy.

J B Konefal, B Emami, M V Pilepich.   

Abstract

Thirty-five patients with 67 measureable cutaneous or lymph node metastases from malignant melanoma were treated with radiation therapy in a variety of total doses and dose fractions. There was no correlation between total dose and response rate. However, there was a strong correlation between fraction size and response rate. There were four (9%) complete responses in 43 lesions treated with fractions less than or equal to 500 rad (5 Gy) compared with 12 (50%) complete responses in 24 lesions treated with fractions greater than 500 rad (5 Gy) (P = .0006). Initial response rate was found to correlate strongly with local control at 1 year. The results were then analyzed with respect to lesion size, cutaneous versus nodal lesions, and site of cutaneous lesion (trunk, head and neck, or extremity). Correlation between fraction size and response rate was independent of lesion size, although there were fewer complete responses with increasing lesion size. Correlation was not seen in nodal lesions but was particularly striking in cutaneous lesions. This correlation was statistically significant only for cutaneous lesions of the extremities.

Entities:  

Mesh:

Year:  1987        PMID: 3112864     DOI: 10.1148/radiology.164.3.3112864

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

Review 1.  Melanoma of the head and neck.

Authors:  Terry A Day; Joshua D Hornig; Anand K Sharma; Frank Brescia; M Boyd Gillespie; Deanne Lathers
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Long-term survival after removal of primary intracranial malignant melanoma. Case report.

Authors:  H Nakagawa; T Hayakawa; K Niiyama; Y Nii; T Yoshimine; S Mori
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

Review 3.  The evolving role of radiation therapy in the management of malignant melanoma.

Authors:  Niloufer Khan; Mohammad K Khan; Alex Almasan; Arun D Singh; Roger Macklis
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-12       Impact factor: 7.038

4.  Concurrent versus sequential application of ferromagnetic hyperthermia and 125I brachytherapy of melanoma in an animal model.

Authors:  W F Mieler
Journal:  Trans Am Ophthalmol Soc       Date:  1997

5.  Malignant melanoma metastatic to the larynx: treatment and functional outcome.

Authors:  B G Lanson; N Sanfilippo; B Wang; D Grew; M D DeLacure
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

6.  Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents.

Authors:  Mohammad K Khan; Niloufer Khan; Alex Almasan; Roger Macklis
Journal:  Onco Targets Ther       Date:  2011-08-09       Impact factor: 4.147

7.  Profiling of plasma metabolites in canine oral melanoma using gas chromatography-mass spectrometry.

Authors:  Mifumi Kawabe; Yuta Baba; Reo Tamai; Ryohei Yamamoto; Masayuki Komori; Takashi Mori; Shigeo Takenaka
Journal:  J Vet Med Sci       Date:  2015-05-04       Impact factor: 1.267

8.  Practice patterns for postoperative radiation therapy in patients with metastases to the long bones: a survey of the Japanese Radiation Oncology Study Group.

Authors:  Hikaru Kubota; Naoki Nakamura; Naoto Shikama; Ayako Tonari; Hitoshi Wada; Hideyuki Harada; Hisayasu Nagakura; Joichi Heianna; Kei Ito; Miwako Nozaki; Masao Tago; Masato Fushiki; Nobue Uchida; Norio Araki; Shuhei Sekii; Takashi Kosugi; Takeo Takahashi; Terufumi Kawamoto; Tetsuo Saito; Kazunari Yamada
Journal:  J Radiat Res       Date:  2021-03-10       Impact factor: 2.724

Review 9.  Surgery and radiotherapy in the treatment of cutaneous melanoma.

Authors:  A Testori; P Rutkowski; J Marsden; L Bastholt; V Chiarion-Sileni; A Hauschild; A M M Eggermont
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

10.  First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Authors:  C Le Tourneau; B Dreno; Y Kirova; J J Grob; T Jouary; C Dutriaux; L Thomas; C Lebbé; L Mortier; P Saiag; M F Avril; E Maubec; P Joly; P Bey; J M Cosset; J S Sun; B Asselain; F Devun; M E Marty; M Dutreix
Journal:  Br J Cancer       Date:  2016-05-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.